Vietnam, August 15, 2024 – The pharmaceutical company STADA is expanding its Consumer Healthcare business in the Asia-Pacific region with the acquisition of Nizoral Cream from Janssen Pharmaceutica NV, a Johnson & Johnson company. The product, which contains the active ingredient ketoconazole, is indicated for the treatment of fungal skin infections.
Under the terms of the agreement, STADA acquires the existing distribution and Nizoral Cream business in the markets of Vietnam, the Philippines, and Thailand, as well as the trademark rights in Hong Kong, Australia, Indonesia, Malaysia, New Zealand, and Singapore.
This transaction represents an extension of a previous asset deal into the APAC region. In 2018, STADA successfully acquired the Nizoral brand in key EMEA markets.
Stéphane Jacqmin, Executive Vice President, Emerging Markets at STADA, stated: “We are delighted to take this important step of expansion in the Asia-Pacific region. This partnership further strengthens STADA’s role as a partner of choice in consumer healthcare”.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharma. STADA sells its products in approximately 115 countries worldwide. In the 2023 financial year, STADA achieved group sales of EUR 3,734.8 million and EBITDA of EUR 802.1 million. As of December 31, 2023, STADA employed 11,667 people globally.
STADA Media Contact
STADA Arzneimittel AG – Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-165 | Fax: +49 (0) 6101 603-215 | Email: press@stada.de
Website: www.stada.com/press
STADA Investor Relations Contact
STADA Arzneimittel AG – Investor & Borrower Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689 | Fax: +49 (0) 6101 603-215 |Email: ir@stada.de
Website: www.stada.com/investor-relations
